Drug intelligence / Profile preview

AMLOPRIL

Development stage
Unknown
Lead developer
GoodMed Healthcare
Modality
Small Molecules
Administration
Oral
01

Overview

AMLOPRIL is a fixed-dose combination pharmaceutical product containing amlodipine and lisinopril, developed and distributed by GoodMed Healthcare for the management of hypertension. Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to peripheral vasodilation and reduced blood pressure. Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor that prevents the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. By inhibiting ACE, lisinopril reduces peripheral vascular resistance and decreases aldosterone secretion, which promotes sodium and water excretion. The combination of these two mechanisms provides a synergistic effect in lowering blood pressure and is used when monotherapy is insufficient.

Brand names
AMLOPRIL
Other names
amlodipine + lisinoprilAmlodipine 5 mg + Lisinopril 5 mg
02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on AMLOPRIL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMLOPRIL.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call